Ligand Lifts 2026 EPS Guidance To $9.50-$9.75 But Keeps Revenue Outlook Unchanged

The CFO called the fourth-quarter royalty implied by unchanged guidance "a measured approach" and cited partners that had not yet reported.

Share
Ligand Lifts 2026 EPS Guidance To $9.50-$9.75 But Keeps Revenue Outlook Unchanged

Ligand Pharmaceuticals, which buys and structures royalty interests in medicines developed by other drug companies, raised its 2026 adjusted earnings guidance to $9.50 to $9.75 a share from $9.00 to $9.50, while leaving revenue guidance untouched, the company said Thursday. On the earnings call, CFO Octavio Espinoza defended the unchanged top line as a deliberately cautious stance.

Guidance raised on one line only

Ligand reaffirmed full-year royalty revenue of $225 million to $250 million and total revenue of $270 million to $310 million, according to the results release. It also kept its Captisol sales outlook at $35 million to $40 million and contract revenue at $10 million to $20 million.

Third-quarter royalty revenue rose 51% from a year earlier to $70.3 million, with legacy royalties up 25% to $58.1 million and the Zoma assets adding $12.3 million since the July 14 close. Adjusted earnings were $2.67 a share, against $3.09 a year earlier, when the company booked $24.5 million of one-time Selzuvme out-license income. On a standard accounting basis, it lost $1.43 a share, hurt in part by $35 million of one-time Zoma deal and integration costs and by mostly non-cash markdowns on equity investments.

Why the top line stayed put

A Barclays analyst noted that unchanged guidance implies fourth-quarter royalty revenue of roughly 64 million to 89 million after a strong quarter. Espinoza agreed the low end "does imply a measured approach," but said he has a "high level of confidence" Ligand will approach the mid to higher end, "if not even exceeded."

Part of the caution, he said, is that many partners had not yet reported. For those, Ligand's estimates draw on sell-side consensus and any difference will be adjusted in the following quarter.

Asked by an Oppenheimer analyst what drives the conservatism, Espinoza said management has line of sight on expenses, share count and tax rates, which inspired the EPS raise. On the top line, he said, order flow from Captisol customers and regulatory and clinical milestones carry uncertainty.

A fourth-quarter-heavy year

Espinoza said 2026 revenue should weigh more heavily on the fourth quarter. It will include a full quarter of Zoma royalties, against a partial one in the third, and tiered royalty rates that step up with sales typically reach their higher tiers later in the year.

Ligand is also reporting earlier than before, a schedule it plans to keep through 2027. Espinoza tied that to its financial royalty asset balance, which rose to $800 million after the Zoma deal from about $200 million last quarter; income on those assets follows long-term cash flow forecasts rather than a single quarter of partner sales.

Filspari, from Travere, became the largest royalty asset at an estimated $16.8 million. Travere reports Monday, November 2, after the close, and any gap from Ligand's estimate will be trued up in the fourth quarter. Ligand will update its long-term outlook at an investor day on December 8.

Ligand ended the quarter with about $450 million in cash and short-term investments, and CEO Todd Davis said it has $750 million of deployable capital.

Sources

More on Ligand Pharmaceuticals

All Ligand Pharmaceuticals (LGND) coverage →